Search results for "molecular medicine"

showing 10 items of 3013 documents

Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy.

2016

Efficacy and toxicity of anthracycline treatment in acute myeloid leukemia (AML) is mediated by reactive oxygen species (ROS). NADPH oxidase is the major endogenous source of ROS and a key mediator of oxidative cardiac damage. The impact of NADPH oxidase polymorphisms (CYBA:rs4673, NCF4:rs1883112, RAC2:rs13058338) was evaluated in 225 adult de novo AML patients. Variant alleles of NCF4 and RAC2 were related to higher complete remission (P=0.035, P=0.016), and CYBA homozygous variant showed lower overall survival with recessive model (P=0.045). Anthracycline-induced cardiotoxicity was associated to NCF4 homozygous variant (P=0.012) and CYBA heterozygous genotype (P=0.027). Novel associations…

0301 basic medicineMaleAnthracyclinePharmacologyBiologyPolymorphism Single NucleotideNephrotoxicity03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsHumansAgedRetrospective StudiesPharmacologychemistry.chemical_classificationReactive oxygen speciesCardiotoxicityNADPH oxidaseRemission InductionMyeloid leukemiaNADPH OxidasesInduction ChemotherapyMiddle Agedrac GTP-Binding ProteinsRac GTP-Binding ProteinsLeukemia Myeloid Acute030104 developmental biologychemistry030220 oncology & carcinogenesisToxicitybiology.proteinMolecular MedicineFemaleReactive Oxygen SpeciesThe pharmacogenomics journal
researchProduct

Plasma heme oxygenase-1 is decreased in peripheral artery disease patients.

2016

Peripheral artery disease (PAD) is a common manifestation of atherosclerosis. A number of emerging risk factors, including oxidative stress biomarkers, free radicals and heat shock proteins, may add to the established risk factors for cardiovascular disease (CVD). The present study assessed surrogate markers of oxidative stress, including total reduced glutathione (GSH), lipid hydroperoxides (LOOH), isoprostanes, heme oxygenase‑1 (HO‑1) and metabolic biomarkers, such as adiponectin and lactate, in PAD patients (n=27). Healthy age‑matched volunteers (n=27) served as controls. GSH and LOOH were evaluated by measuring total thiol groups and iron oxidation, respectively, by spectrophotometric a…

0301 basic medicineMaleCancer Researchmedicine.medical_specialtyAdipokineOxidative phosphorylationBiologyIsoprostanesmedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compoundPeripheral Arterial DiseaseInternal medicineGeneticsmedicineHumansAnkle Brachial IndexMolecular BiologyAgedAdiponectinGlutathioneMiddle Agedmedicine.diseaseIsoprostanesGlutathioneHeme oxygenaseOxidative Stress030104 developmental biologyEndocrinologyOncologychemistryImmunologyMolecular MedicineFemaleAdiponectinLipid PeroxidationOxidative stressDyslipidemiaBiomarkersHeme Oxygenase-1Molecular medicine reports
researchProduct

Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets

2021

In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high‐risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post‐transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker‐directed fashion.

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentRetinoic acidchemistry.chemical_compoundNeuroblastoma0302 clinical medicineTumor Microenvironment11q deletion anti-GD2 immunotherapy combination immunotherapy immune cell infiltration miRNAs neuroblastomaMedicineeducation.field_of_studyimmune cell infiltration11q deletionImmunosuppressionGeneral Medicinelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPatologiaNeoplasm ProteinsmicroRNAsSurvival Rateanti‐GD2 therapyOncology030220 oncology & carcinogenesiscombination immunotherapymiRNAsMolecular Medicineimmune checkpoint inhibitionFemaleImmunotherapyChromosome Deletionanti‐GD2 immunotherapyPopulationlcsh:RC254-282Disease-Free Survival03 medical and health sciencesImmune systemNeuroblastomaGeneticsImmune ToleranceHumanseducationRetrospective Studiesbusiness.industryChromosomes Human Pair 11Immunotherapymedicine.diseaseImmune checkpointBlockade030104 developmental biologychemistryCancer researchCommentarybusiness
researchProduct

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity

2021

BackgroundTumor microenvironment-associated T cell senescence is a key limiting factor for durable effective cancer immunotherapy. A few studies have demonstrated the critical role of the tumor suppressor TP53-derived p53 isoforms in cellular senescence process of non-immune cells. However, their role in lymphocytes, in particular tumor-antigen (TA) specific T cells remain largely unexplored.MethodsHuman T cells from peripheral blood were retrovirally engineered to coexpress a TA-specific T cell receptor and the Δ133p53α-isoform, and characterized for their cellular phenotype, metabolic profile and effector functions.ResultsPhenotypic analysis of Δ133p53α-modified T cells revealed a marked …

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentT cellT-LymphocytesImmunologyReceptors Antigen T-Cell2436receptorsBiologycell engineeringadoptive03 medical and health sciencesMice0302 clinical medicineantigenTIGITCancer immunotherapyAntigenCell Line TumorNeoplasmsmedicineTumor MicroenvironmentImmunology and AllergyAnimalsHumans1506RC254-282PharmacologyImmune Cell Therapies and Immune Cell EngineeringCD28Neoplasms. Tumors. Oncology. Including cancer and carcinogensT lymphocyteImmunotherapycostimulatory and inhibitory T-cell receptorsCell biology030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisMolecular MedicineimmunotherapyCD8Journal for ImmunoTherapy of Cancer
researchProduct

Retrospective study of small pet tumors treated with Artemisia annua and iron.

2019

Artemisinin from Artemisia annua L. and its derivatives are well‑known antimalarial drugs. In addition, in vitro studies, in vivo studies and clinical trials have demonstrated that these drugs exhibit anticancer activity in human patients with cancer. Therefore, the aim of the present study was to investigate whether a phytotherapeutic A. annua preparation exerts anticancer activity in veterinary tumors of small pets. Dogs and cats with spontaneous cancer (n=20) were treated with standard therapy plus a commercial A. annua preparation (Luparte®) and compared with a control group treated with standard therapy alone (n=11). Immunohistochemical analyses were performed with formalin‑fixed paraf…

0301 basic medicineMaleCancer Researchnatural productsIronArtemisia annuaTransferrin receptorApoptosisBiologyPharmacologyArtemisia annuaAsteraceaeCat Diseaseschemotherapy03 medical and health sciences0302 clinical medicineDogsIn vivomedicineTumor Cells CulturedAnimalsDog DiseasesArtemisininProspective cohort studyCell ProliferationRetrospective StudiesOncogenePlant ExtractsCancerphytotherapyprognostic factorsNeoplasms ExperimentalArticlesbiology.organism_classificationmedicine.diseaseMolecular medicine030104 developmental biologyOncologyartemisinin030220 oncology & carcinogenesisCatsFemalemedicine.drugInternational journal of oncology
researchProduct

Silencing of hepatic fate-conversion factors induce tumorigenesis in reprogrammed hepatic progenitor-like cells

2016

Abstract Background Several studies have reported the direct conversion of mouse fibroblasts to hepatocyte-like cells with different degrees of maturation by expression of hepatic fate-conversion factors. Methods We have used a combination of lentiviral vectors expressing hepatic fate-conversion factors with Oct4, Sox2, Klf4, and Myc to convert mouse embryonic fibroblasts into hepatic cells. Results We have generated hepatic cells with progenitor-like features (iHepL cells). iHepL cells displayed basic hepatocyte functions but failed to perform functions characteristic of mature hepatocytes such as significant Cyp450 or urea cycle activities. iHepL cells expressed multiple hepatic-specific …

0301 basic medicineMaleCarcinogenesisCellular differentiationMedicine (miscellaneous)Gene ExpressionReceptors G-Protein-CoupledMiceMice Inbred NODHepatocyteTransgenesStem CellsTeratomaCell DifferentiationForkhead Transcription FactorsCellular ReprogrammingCell biologyKLF4Molecular MedicineStem cellReprogrammingDirect reprogrammingGenetic VectorsKruppel-Like Transcription FactorsBiologyBiochemistry Genetics and Molecular Biology (miscellaneous)Proto-Oncogene Proteins c-myc03 medical and health sciencesKruppel-Like Factor 4SOX2AnimalsHepatectomyGene SilencingProgenitor cellResearchXenograftSOXB1 Transcription FactorsLentivirusCD24 AntigenCell BiologyFibroblastsEmbryo MammalianEmbryonic stem cell030104 developmental biologyTumorigenesisHepatic stellate cellHepatocytesOctamer Transcription Factor-3BiomarkersProgenitorStem Cell Research & Therapy
researchProduct

Assessment of Targeted Next-Generation Sequencing as a Tool for the Diagnosis of Charcot-Marie-Tooth Disease and Hereditary Motor Neuropathy

2016

Charcot-Marie-Tooth disease is characterized by broad genetic heterogeneity with >50 known disease-associated genes. Mutations in some of these genes can cause a pure motor form of hereditary motor neuropathy, the genetics of which are poorly characterized. We designed a panel comprising 56 genes associated with Charcot-Marie-Tooth disease/hereditary motor neuropathy. We validated this diagnostic tool by first testing 11 patients with pathological mutations. A cohort of 33 affected subjects was selected for this study. The DNAJB2 c.352+1G>A mutation was detected in two cases; novel changes and/or variants with low frequency (50 known disease-associated genes. Mutations in some of these gene…

0301 basic medicineMaleDiseaseBioinformaticsDNA sequencingPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineCharcot-Marie-Tooth DiseaseMedicineHumansGeneGeneticsbusiness.industryGenetic heterogeneityHaplotypeCase-control studyHigh-Throughput Nucleotide SequencingReproducibility of ResultsHSP40 Heat-Shock Proteins030104 developmental biologyHaplotypesCase-Control StudiesMutation (genetic algorithm)MutationMolecular MedicineFemalebusinessHereditary Sensory and Motor Neuropathy030217 neurology & neurosurgeryFounder effectMolecular Chaperones
researchProduct

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohor…

2019

Abstract Background Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals). Patients were evaluated at baseline, week 24 and 48. Changes were evaluated using the paired t test or signed rank test. The multivariable analysis was performed using a general linear model, after ranking of not normally distributed variables. Results A total of 249 patients were included, 72 (29%) were in DRV/c-based dual therapies (DT). Hypercholesterolemia, HC, (total cholesterol (TC) ≥ 200 mg/dL or low density-C (LDL-C) ≥ 13…

0301 basic medicineMaleHIV Infections0302 clinical medicineDualMedicineHIV InfectionPharmacology (medical)030212 general & internal medicineProspective StudiesProspective cohort studyDarunavirCobicistatMiddle AgedViral LoadTolerabilityTolerabilityAnti-Retroviral AgentsCohortMolecular MedicineDrug Therapy CombinationFemaleDarunavir/cobicistatHumanmedicine.drugAdverse eventAdultlcsh:Immunologic diseases. Allergymedicine.medical_specialty030106 microbiologyContext (language use)Durability03 medical and health sciencesDarunavir/cobicistat Dual Durability Tolerability CISAI Adverse eventsVirologyInternal medicineHumansDarunavirbusiness.industryResearchHypertriglyceridemiamedicine.diseaseCISAIDiscontinuationProspective StudieAdverse eventsHIV-1Anti-Retroviral AgentCobicistatbusinesslcsh:RC581-607
researchProduct

Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patient…

2017

Background The use of stem cells, including mesenchymal stem cells (MSCs), for regenerative medicine is gaining interest for the clinical benefits so far obtained in patients. This study investigates the use of adipose autologous tissue in combination with platelet-rich plasma (PRP) to improve the clinical outcome of patients affected by systemic sclerosis (SSc). Methods Adipose-derived mesenchymal stem cells (AD-MSCs) and PRPs were purified from healthy donors and SSc patients. The multilineage differentiation potential of AD-MSCs and their genotypic–phenotypic features were investigated. A cytokine production profile was evaluated on AD-MSCs and PRPs from both healthy subjects and SSc pat…

0301 basic medicineMalePathologyCell- and Tissue-Based TherapyAdipose tissueMedicine (miscellaneous)Gene ExpressionRegenerative MedicineCell therapyCell therapySystemic sclerosiAdipose-derived mesenchymal stem cells; Cell therapy; Lipofilling; Mesenchymal stem cells; Platelet-rich plasma; Regenerative medicine; Systemic sclerosis; Medicine (miscellaneous); Molecular Medicine; Biochemistry Genetics and Molecular Biology (miscellaneous); Cell Biologylcsh:QD415-436skin and connective tissue diseasesMesenchymal stem cellSkinAged 80 and overlcsh:R5-920integumentary systemCell DifferentiationStromal vascular fractionMiddle Agedmedicine.anatomical_structureAdipose TissueMolecular MedicineCytokinesSystemic sclerosisFemaleStem celllcsh:Medicine (General)Adultmedicine.medical_specialtyPrimary Cell CultureConnective tissueNeovascularization PhysiologicMesenchymal Stem Cell TransplantationBiochemistry Genetics and Molecular Biology (miscellaneous)lcsh:Biochemistry03 medical and health sciencesPlatelet-rich plasmaAntigens CDAdipose-derived mesenchymal stem cellsmedicineHumansCell ProliferationAdipose-derived mesenchymal stem cellLipofillingScleroderma Systemicbusiness.industryRegeneration (biology)ResearchMesenchymal stem cellMesenchymal Stem CellsCell Biology030104 developmental biologyPlatelet-rich plasmaImmunologybusinessStem cell researchtherapy
researchProduct

Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers

2015

// Giorgio Mauri 1 , Elena Jachetti 1 , Barbara Comuzzi 1 , Matteo Dugo 2 , Ivano Arioli 1 , Silvia Miotti 1 , Sabina Sangaletti 1 , Emma Di Carlo 3, 4 , Claudio Tripodo 5 , Mario P. Colombo 1 1 Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, 20133, Milano, Italy 2 Functional Genomics and Bioinformatics, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, 20133, Milano, Italy 3 Department of Medicine and Science of Aging, Section of Anatomic Pathology and Molecular Medicine, “G. d’Annunzio” University, 66100, Chieti, Italy 4 Ce.S.I. Aging Research Center, “G…

0301 basic medicineMalePathologyFluorescent Antibody Techniquemedicine.disease_causeImmunoenzyme TechniquesProstate cancerMice0302 clinical medicineOsteopontinProstate cancerbiologyReverse Transcriptase Polymerase Chain ReactionExtracellular matrixNeuroendocrine TumorsCell Transformation NeoplasticNeuroendocrineOncology030220 oncology & carcinogenesisDisease ProgressionAdenocarcinomaTrampResearch Papermedicine.medical_specialtyBlotting WesternMice TransgenicAdenocarcinomaSettore MED/08 - Anatomia PatologicaReal-Time Polymerase Chain Reaction03 medical and health sciencesstomatognathic systemmedicineAnimalsHumansExtracellular matrix; Neuroendocrine; Osteopontin; Prostate cancer; OncologyRNA Messengerbusiness.industryGene Expression ProfilingCancerProstatic Neoplasmsmedicine.diseaseMolecular medicineMice Inbred C57BLDisease Models Animal030104 developmental biologyTumor progressionbiology.proteinOsteopontinCarcinogenesisbusinessGene Deletion
researchProduct